Drug Discovery MarketSize, Share & Industry Analysis, 2026-2034By WorkflowBy Therapeutics AreaBy Drug TypeBy TypeBy End-user

Drug discovery covers the research services and platforms used to identify, validate and optimize new therapeutic candidates before they enter formal preclinical testing, spanning target identification, hit-to-lead chemistry, biological screening and early candidate characterization. Work is carried out both in-house by pharmaceutical and biotechnology research teams and through contract research organizations that provide chemistry, biology and informatics capacity on an outsourced basis. Buyers range from large pharmaceutical companies running internal pipelines to smaller biotechnology firms and academic research groups that rely on external providers for specialized screening and validation capabilities.

Growth of 9.2% a year carries the global drug discovery market from USD 74.5 billion in 2025 to USD 164.78 billion in 2034. The full series behind that rate covers USD 47.33 billion in 2020, USD 68.05 billion in 2024, USD 81.5 billion in 2026 and USD 115.89 billion in 2030, with 2025 as the base year.

32% of 2025 revenue sits in Lead Identification & Candidate Optimization, worth USD 23.84 billion and rising to USD 51.08 billion at 31% by 2034, the largest workflow line in both years. Growth is fastest in Target Identification & Screening at 10.76% and slowest in Preclinical Development at 8.31%. The lines gaining share are Target Identification & Screening. Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development and Other Associated Workflow lose share without losing revenue.

The therapeutics area split puts Oncology first, at USD 19.37 billion and 26% of revenue in 2025, rising to USD 46.14 billion and 28% in 2034. Immunomodulation grows faster at 10.5% against 10.13%, moving from 9% of revenue to 10% by 2034. It cuts the same total as the workflow axis from a different commercial angle, so revenue does not add across the two.

USD 31.29 billion of 2025 revenue is generated in North America, 42% of the global total and the largest regional share; it reaches USD 62.62 billion by 2034. Asia Pacific is next at 27% and USD 20.12 billion, and Middle East and Africa last at 3%. Because Asia Pacific take share, the revenue added by 2034 concentrates rather than spreading across all five regions.

Behind these figures sit five regions, five workflow lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

• The global drug discovery market moves from USD 47.33 billion in 2020 to USD 74.5 billion in 2025 and USD 164.78 billion by 2034, the forecast period compounding at 9.2% a year.
• Lead Identification & Candidate Optimization is the largest workflow line at USD 23.84 billion in 2025, a 32% share, reaching USD 51.08 billion and 31% of revenue by 2034.
• At 10.76%, Target Identification & Screening grows faster than any other workflow line, moving from USD 16.39 billion and 22% of revenue in 2025 to USD 41.2 billion and 25% in 2034.
• Against a base case of USD 164.78 billion in 2034, the study also reports a bear case at USD 148.3 billion and a bull case at USD 181.26 billion, with the assumptions behind each set out separately.
• North America holds 42% of global revenue in 2025 at USD 31.29 billion, the largest of the five regions tracked, and reaches USD 62.62 billion by 2034.
• 85% of North America's base-year revenue comes from the United States alone: USD 26.6 billion in 2025, rising to USD 53.23 billion by 2034, which is why it is that region's worked example.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three movements define the forecast period in the global drug discovery market: how the workflow mix changes, where regional weight shifts, and the rate at which the total compounds.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; the question is which takes the larger part of the growth.

Target Identification & Screening grows faster than Preclinical Development. Between 2026 and 2034, 10.76% growth in Target Identification & Screening against 8.31% in Preclinical Development pulls the workflow mix apart. By 2034 the two sit at 25% and 26% of revenue, against 22% and 28% in 2025. In absolute terms Target Identification & Screening rises from USD 16.39 billion to USD 41.2 billion, while Preclinical Development rises from USD 20.86 billion to USD 42.84 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Growth concentrates in Asia Pacific. Asia Pacific moves from 27% of revenue in 2025 to 33% in 2034, worth USD 20.12 billion rising to USD 54.38 billion. The remaining regions grow in absolute terms while giving up share: North America at 42% moving to 38%, Europe at 24% moving to 22%, Latin America at 4% moving to 4%, Middle East and Africa at 3% moving to 3%. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

Growth compounds at 9.2% without a step change. Reading the series: USD 47.33 billion in 2020, USD 68.05 billion in 2024, USD 74.5 billion in 2025, USD 81.5 billion in 2026, USD 115.89 billion in 2030 and USD 164.78 billion in 2034. There is no discontinuity to time, and 9.2% forecast growth against 9.5% historical means the trend continues rather than turns. That moves the planning question away from timing a turn and onto the workflow and regional mixes, where the actual movement is.

Growth is concentrated in Target Identification & Screening

The 9.2% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the workflow axis, and where regional growth is concentrated.

Downside case: USD 148.3 billion rather than USD 164.78 billion by 2034

What the bull case turns on

Revenue is concentrated in Lead Identification & Candidate Optimization

USD 31.29 billion of 2025 revenue is generated in North America, 42% of the global drug discovery market rising to USD 62.62 billion in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Share settles at 38% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

Lead Identification & Candidate Optimization leads here as it does globally, at 32% of 2025 revenue, and Target Identification & Screening again grows fastest at 10.76%. North America is reported axis by axis and country by country in the full study.

The largest single market in North America is the United States, at USD 26.6 billion in 2025 and USD 53.23 billion in 2034. 85% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. The region itself runs USD 31.29 billion to USD 62.62 billion over the same period, and this is the market carrying the country-level detail in the full report.

the United States buys along the same lines as the market globally; Lead Identification & Candidate Optimization first at 32% of 2025 revenue and 31% in 2034, Target Identification & Screening fastest at 10.76% on a share moving from 22% to 25%. Its 85% weight in North America means those movements carry straight into the regional totals. Per-workflow revenue for the United States appears on its own in the full report.

Drug discovery activity in the United States sits upstream of formal product approval, but the tools, assays, and contract services that generate nonclinical data are still governed by the Food and Drug Administration's Good Laboratory Practice regulations, which set requirements for study conduct, data integrity, and record retention wherever findings are intended to support a future Investigational New Drug application. Laboratories using animal models must operate under Institutional Animal Care and Use Committee oversight per the Animal Welfare Act, and any software used to capture or manage research data is expected to meet FDA data integrity and audit-trail expectations. Suppliers of discovery instruments and reagents typically position their offerings as research-use-only, a labelling distinction that keeps them outside clinical-grade regulatory scope.

The suppliers tracked in this study (Albany Molecular Research Inc., EVOTEC, Laboratory Corporation of America Holdings, GenScript, Pharmaceutical Product Development, LLC, Charles River, WuXi AppTec, Merck & Co., Inc., Thermo Fisher Scientific Inc., Dalton Pharma Services, Oncodesign, Jubilant Biosys, DiscoverX Corp., QIAGEN, Eurofins SE, Syngene International Limited, Dr. Reddy Laboratories Ltd., Pharmaron Beijing Co., Ltd., TCG Lifesciences Pvt Ltd. and Domainex Ltd.) compete in the United States across the workflow lines above. Two different problems sit on the same axis: holding Lead Identification & Candidate Optimization at 32% of 2025 revenue, and taking Target Identification & Screening while it grows at 10.76%. The full report covers country-level positioning and shares company by company; this summary does not.

4.2% of global revenue is generated in Canada; USD 3.13 billion in 2025, reaching USD 6.26 billion in 2034, and 10% of North America.

USD 17.88 billion of 2025 revenue is generated in Europe, 24% of the global drug discovery market and reaches USD 36.25 billion by 2034. Among the five regions it ranks third by revenue in both years.

Share settles at 22% in 2034, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the workflow split tracks the global one; 32% of 2025 revenue in Lead Identification & Candidate Optimization, fastest growth of 10.76% in Target Identification & Screening. The full report breaks Europe out along every axis and by country.

USD 6.26 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 12.69 billion by 2034. Its 35% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. The region itself runs USD 17.88 billion to USD 36.25 billion over the same period, and this is the market carrying the country-level detail in the full report.

The workflow pattern in Germany is the global one: 32% of 2025 revenue in Lead Identification & Candidate Optimization, 31% by 2034, against 10.76% growth in Target Identification & Screening taking it from 22% to 25%. With 35% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by workflow for Germany is reported separately in the full report.

As an European Union member state, Germany applies the bloc's shared framework for nonclinical pharmaceutical research alongside its own implementing law. Good Laboratory Practice principles, enforced domestically through state-level GLP monitoring authorities, govern the conduct and documentation of discovery-stage studies intended to support later clinical development. Animal-based research is additionally regulated under the Tierschutzgesetz, Germany's animal welfare law, which requires ethical review and authorisation before procedures may proceed. Providers of laboratory instruments and diagnostic-adjacent equipment must show conformity with applicable EU product safety and, where relevant, in-vitro diagnostic frameworks, while any personal or genomic data handled during research is subject to the General Data Protection Regulation. Research-use-only labelling is standard practice for discovery tools not intended for clinical use.

Competition in Germany runs between the suppliers this study tracks: Albany Molecular Research Inc., EVOTEC, Laboratory Corporation of America Holdings, GenScript, Pharmaceutical Product Development, LLC, Charles River, WuXi AppTec, Merck & Co., Inc., Thermo Fisher Scientific Inc., Dalton Pharma Services, Oncodesign, Jubilant Biosys, DiscoverX Corp., QIAGEN, Eurofins SE, Syngene International Limited, Dr. Reddy Laboratories Ltd., Pharmaron Beijing Co., Ltd., TCG Lifesciences Pvt Ltd. and Domainex Ltd.. Volume sits in Lead Identification & Candidate Optimization at 32% of 2025 revenue; movement sits in Target Identification & Screening at 10.76% growth.

The United Kingdom is sized at USD 4.47 billion in 2025, rising to USD 9.06 billion by 2034; 6% of global revenue and 25% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

In Asia Pacific, 27% of global revenue puts 2025 at USD 20.12 billion on the way to USD 54.38 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Share climbs to 33% by 2034, because it outgrows the market's 9.2%; the revenue added here is disproportionate to where the region started.

Lead Identification & Candidate Optimization leads here as it does globally, at 32% of 2025 revenue, and Target Identification & Screening again grows fastest at 10.76%. Per-axis and per-country detail for Asia Pacific sits in the full report.

40% of Asia Pacific's base-year revenue comes from China; USD 8.05 billion, rising to USD 21.75 billion by 2034. 40% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 20.12 billion in 2025 and USD 54.38 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Lead Identification & Candidate Optimization at 32% of 2025 revenue, easing to 31% by 2034, and the fastest is Target Identification & Screening at 10.76%, from 22% to 25%. Because the country carries 40% of Asia Pacific, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports China by workflow separately.

Drug discovery work in China falls under the oversight of the National Medical Products Administration, which sets the framework nonclinical studies must satisfy before a candidate can advance toward a clinical trial application. Laboratories generating pivotal nonclinical data are expected to operate under Good Laboratory Practice certification issued through national inspection authorities. Where discovery work involves human genetic material, providers and researchers must additionally comply with China's human genetic resources regulations, which govern the collection, export, and international sharing of such samples and data. Animal research is subject to institutional ethics review consistent with national laboratory animal welfare guidance. Instruments and reagents marketed for research use are generally distinguished by labelling from those intended for clinical or diagnostic application, keeping them outside stricter medical device pathways.

Albany Molecular Research Inc., EVOTEC, Laboratory Corporation of America Holdings, GenScript, Pharmaceutical Product Development, LLC, Charles River, WuXi AppTec, Merck & Co., Inc., Thermo Fisher Scientific Inc., Dalton Pharma Services, Oncodesign, Jubilant Biosys, DiscoverX Corp., QIAGEN, Eurofins SE, Syngene International Limited, Dr. Reddy Laboratories Ltd., Pharmaron Beijing Co., Ltd., TCG Lifesciences Pvt Ltd. and Domainex Ltd. are the suppliers covered in China. The commercially relevant division is 32% of 2025 revenue in Lead Identification & Candidate Optimization, where the volume is, against 10.76% growth in Target Identification & Screening, where share moves.

India is sized at USD 5.03 billion in 2025, rising to USD 13.6 billion by 2034; 6.8% of global revenue and 25% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Within Asia Pacific, Japan accounts for 20% of regional revenue and 5.4% of the global total, worth USD 4.02 billion in 2025 and USD 10.88 billion by 2034.

In Latin America, 4% of global revenue puts 2025 at USD 2.98 billion and reaches USD 6.59 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

By 2034 the share stands at 4%, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the workflow split tracks the global one; 32% of 2025 revenue in Lead Identification & Candidate Optimization, fastest growth of 10.76% in Target Identification & Screening. The full report breaks Latin America out along every axis and by country.

USD 1.49 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 3.3 billion by 2034. At 50% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 2.98 billion to USD 6.59 billion over the same period, and this is the market carrying the country-level detail in the full report.

Brazil buys along the same lines as the market globally; Lead Identification & Candidate Optimization first at 32% of 2025 revenue and 31% in 2034, Target Identification & Screening fastest at 10.76% on a share moving from 22% to 25%. With 50% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Brazil carries its own workflow breakdown in the full report.

In Brazil, the Agência Nacional de Vigilância Sanitária, or ANVISA, oversees the regulatory environment surrounding pharmaceutical research, including the standards nonclinical studies must meet before supporting a clinical trial submission. Laboratories conducting discovery-stage safety and pharmacology studies are expected to follow Good Laboratory Practice principles recognised by national accreditation bodies. Research involving animals is subject to review by CONCEA, the National Council for Control of Animal Experimentation, which authorises institutions and oversees ethical compliance. Providers of laboratory instruments, reagents, and screening technologies typically label their products for research use only, distinguishing them from items requiring ANVISA's medical device or diagnostic registration pathways. Data generated for regulatory submission purposes must be traceable and auditable under applicable good practice guidance.

In Brazil the field is Albany Molecular Research Inc., EVOTEC, Laboratory Corporation of America Holdings, GenScript, Pharmaceutical Product Development, LLC, Charles River, WuXi AppTec, Merck & Co., Inc., Thermo Fisher Scientific Inc., Dalton Pharma Services, Oncodesign, Jubilant Biosys, DiscoverX Corp., QIAGEN, Eurofins SE, Syngene International Limited, Dr. Reddy Laboratories Ltd., Pharmaron Beijing Co., Ltd., TCG Lifesciences Pvt Ltd. and Domainex Ltd.. The commercially relevant division is 32% of 2025 revenue in Lead Identification & Candidate Optimization, where the volume is, against 10.76% growth in Target Identification & Screening, where share moves.

Mexico is sized at USD 0.89 billion in 2025, rising to USD 1.98 billion by 2034; 1.2% of global revenue and 29.9% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

In Middle East and Africa, 3% of global revenue puts 2025 at USD 2.24 billion rising to USD 4.94 billion in 2034. Among the five regions it ranks fifth by revenue in both years.

By 2034 the share stands at 3%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the workflow split tracks the global one; 32% of 2025 revenue in Lead Identification & Candidate Optimization, fastest growth of 10.76% in Target Identification & Screening. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

USD 1.01 billion of Middle East and Africa's 2025 revenue is generated in Israel, the region's largest market, reaching USD 2.22 billion by 2034. It accounts for 45.1% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 2.24 billion and USD 4.94 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Israel buys along the same lines as the market globally; Lead Identification & Candidate Optimization first at 32% of 2025 revenue and 31% in 2034, Target Identification & Screening fastest at 10.76% on a share moving from 22% to 25%. Since 45.1% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Revenue by workflow for Israel is reported separately in the full report.

Drug discovery research in Israel is overseen within the framework administered by the Ministry of Health, which sets expectations for nonclinical studies feeding into later clinical trial applications, generally aligned with internationally recognised Good Laboratory Practice standards. Research involving animals requires authorisation and ethical review under Israel's Animal Welfare Law and associated institutional animal care committees, while human-subject-adjacent research protocols are reviewed by Helsinki Committees operating under Ministry of Health guidance. Suppliers of discovery instruments, reagents, and screening platforms typically label their products for research use only, placing them outside the stricter registration pathway that applies to clinical and diagnostic devices. Data protection obligations under Israeli privacy law apply where research involves identifiable health-related information.

Competition in Israel runs between the suppliers this study tracks: Albany Molecular Research Inc., EVOTEC, Laboratory Corporation of America Holdings, GenScript, Pharmaceutical Product Development, LLC, Charles River, WuXi AppTec, Merck & Co., Inc., Thermo Fisher Scientific Inc., Dalton Pharma Services, Oncodesign, Jubilant Biosys, DiscoverX Corp., QIAGEN, Eurofins SE, Syngene International Limited, Dr. Reddy Laboratories Ltd., Pharmaron Beijing Co., Ltd., TCG Lifesciences Pvt Ltd. and Domainex Ltd.. Volume sits in Lead Identification & Candidate Optimization at 32% of 2025 revenue; movement sits in Target Identification & Screening at 10.76% growth.

Within Middle East and Africa, South Africa accounts for 25% of regional revenue and 0.8% of the global total, worth USD 0.56 billion in 2025 and USD 1.24 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by workflow, therapeutics area, drug type, type, end-user, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.